^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NP-G2-044

    i
    Other names: NP-G2-044, NP G2 044, DC05F01
    Associations

    News

    Trials
    Company:
    CR Double-Crane, Novita Pharma, Protheragen
    Drug class:
    Fascin inhibitor
    Associations

    News

    Trials
    1m
    NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov)
    P1/2, N=140, Recruiting, Novita Pharmaceuticals, Inc. | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    NP-G2-044
    2ms
    Low YTHDC1 Expression Upregulates FSCN1 to Promote Nuclear F-Actin Formation and Facilitate Double-strand DNA Breaks Repair in TMZ-Resistant Glioblastoma. (PubMed, Adv Sci (Weinh))
    Although temozolomide (TMZ) is a cornerstone of GBM treatment, its efficacy is often compromised by inherent or acquired resistance, underscoring the urgent need to uncover molecular mechanisms, discover new therapeutic targets, and develop innovative treatment strategies. Importantly, combining the FSCN1 inhibitor NP-G2-044, with TMZ therapy resulted in stronger anti-tumor effects both in vitro and in vivo. In conclusion, the study demonstrates that nuclear F-actin formation in GBM promotes DSB repair and reveals that targeting FSCN1 with NP-G2-044 could be a promising strategy for enhancing treatment outcomes and improving the prognosis for GBM patients.
    Journal
    |
    CDC42 (Cell Division Cycle 42) • FSCN1 (Fascin Actin-Bundling Protein 1) • YTHDC1 (YTH Domain Containing 1)
    |
    temozolomide • NP-G2-044
    5ms
    Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) (clinicaltrials.gov)
    P2/3, N=380, Recruiting, Novita Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    |
    NP-G2-044
    7ms
    Trial of NP-G2-044 Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P2/3, N=380, Not yet recruiting, Novita Pharmaceuticals, Inc.
    New P2/3 trial • Platinum resistant
    |
    NP-G2-044
    7ms
    Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=23, Completed, Novita Pharmaceuticals, Inc. | Phase classification: P1a --> P1
    Phase classification
    |
    NP-G2-044
    9ms
    NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov)
    P1/2, N=140, Recruiting, Novita Pharmaceuticals, Inc. | Trial completion date: Sep 2025 --> Mar 2026 | Trial primary completion date: Sep 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    NP-G2-044
    over1year
    NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov)
    P1/2, N=140, Recruiting, Novita Pharmaceuticals, Inc. | N=100 --> 140
    Enrollment change
    |
    EGFR (Epidermal growth factor receptor)
    |
    NP-G2-044
    over1year
    Fascin Inhibitor NP-G2-044 Decreases Cell Metastasis and Increases Overall Survival of Mice-Bearing Lung Cancers. (PubMed, Curr Mol Med)
    Fascin inhibition could inhibit the metastasis of NSCLC and has the potential to enhance the efficacy of cisplatin and PD-1 inhibitors by blocking the Wnt/β- catenin pathway.
    Preclinical • Journal
    |
    CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2)
    |
    cisplatin • NP-G2-044
    over1year
    NP-G2-044 As Monotherapy and Combination Therapy in Patients with Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Novita Pharmaceuticals, Inc. | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    NP-G2-044
    almost2years
    KAT8/SIRT7-mediated Fascin-K41 acetylation/deacetylation regulates tumor metastasis in esophageal squamous cell carcinoma. (PubMed, J Pathol)
    Importantly, K41 acetylation significantly blocked NP-G2-044, one of the Fascin inhibitors currently being clinically evaluated, suggesting that NP-G2-044 may be more suitable for patients with low levels of Fascin-K41 acetylation, but not suitable for patients with high levels of Fascin-K41 acetylation.
    Journal
    |
    FSCN1 (Fascin Actin-Bundling Protein 1) • SIRT7 (Sirtuin 7)
    |
    NP-G2-044
    2years
    NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Novita Pharmaceuticals, Inc.
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    NP-G2-044
    over2years
    NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Novita Pharmaceuticals, Inc. | Trial completion date: Sep 2023 --> Jun 2024 | Trial primary completion date: Mar 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    NP-G2-044